AKR1C3 and urinary bladder cancer: A chromene derivative 2j, which could function as a selective inhibitor for AKR1C3, was found to inhibit the expression of AR and ELK1 in bladder cancer cells and enhance the cytotoxic activity of gemcitabine + cisplatin.